New oncology focus, Fortis’s cancer care program sharpens its hospital offering

Fortis Healthcare is pushing oncology to the center of its portfolio with a structured cancer care program across key hospitals, bundling diagnostics, surgery, chemo and radiation under one coordinated umbrella.

Edited by ad hoc news New Releases & Launches Desk. Reviewed before publication on 06/16/2026 at 5:46 AM ET. Details in the imprint.

Fortis Healthcare is moving oncology even closer to the core of its business with a structured cancer care program that ties together diagnostics, medical oncology, surgical oncology and radiation therapy across its major hospitals in India. Flagship sites such as Fortis Memorial Research Institute in Gurugram, Fortis Hospital in Mohali and Fortis Hospital on Bannerghatta Road in Bengaluru position oncology as an integrated service line rather than a collection of individual departments, with a strong emphasis on multidisciplinary tumor boards and standardized treatment pathways according to the company’s official oncology specialty pages.

How Fortis structures its cancer care program

The Fortis cancer care program is built around three core pillars: early detection, multimodality treatment and long-term survivorship support, according to the group’s descriptions of oncology services at multiple hospitals. Early detection is anchored in imaging (CT, MRI, PET-CT), endoscopy and pathology labs that feed into organ-specific clinics for breast, lung, gastrointestinal and uro-oncology cases, with several facilities promoting one-stop breast and comprehensive cancer clinics on their hospital pages. Treatment options typically span complex oncologic surgery, systemic therapy including chemotherapy and targeted agents, and advanced radiation techniques such as intensity-modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT) where equipment is installed.

Multidisciplinary tumor boards are a core element of the program structure, bringing together medical, surgical and radiation oncologists along with radiologists and pathologists to define individual treatment plans rather than leaving decisions to a single specialist. Fortis highlights such tumor boards and organ-specific clinics at hospitals like Mohali and Gurugram to market the program as coordinated, “team-based” care, which is now standard positioning for large private hospital chains in India’s oncology market. Sub-specialization is also visible in the way Fortis promotes distinct programs in hemato-oncology, pediatric oncology and bone marrow transplant at selected sites, adding depth to what could otherwise be a generic “cancer center” label.

On the survivorship side, Fortis oncology units increasingly emphasize rehabilitation, nutrition and psychological counseling, reflecting a broader industry trend toward managing late effects and quality of life rather than focusing only on active treatment. This includes patient education sessions, physiotherapy for post-surgical recovery and nurse-led follow-up pathways, according to hospital-level program descriptions. Supporting services such as pain management clinics and palliative care teams are promoted at several Fortis hospitals as part of the same continuum, which helps the company present oncology as a full life-cycle product rather than an episodic intervention.

The geographic spread of the cancer care program matters commercially: Fortis uses a hub-and-spoke model in which marquee hospitals like Fortis Memorial Research Institute act as referral centers for complex oncologic surgery and transplants, while regional Fortis facilities focus on diagnostics, chemotherapy and follow-up care. This structure is typical for Indian private hospital chains targeting both metro-city and tier-2 demand, and it allows Fortis to promote oncology packages and screening camps that funnel patients into higher-end treatments at the hubs. Public-facing health campaigns, such as a recently promoted bladder health session at Fortis Hospital Bannerghatta Road in Bengaluru, support that funnel by raising awareness of symptoms that may require specialist evaluation; the hospital advertised such a session on its social channels in June 2026, highlighting urology and uro-oncology expertise in the process, as seen in a recent Instagram post by Fortis Hospital Bannerghatta Road.

From a market perspective, oncology sits alongside cardiac science and neurosciences as one of Fortis Healthcare’s flagship clinical specialties, and management has repeatedly pointed to cancer care and related transplants as growth drivers in India’s rising non-communicable disease burden. The structured cancer care program fits this strategy by offering relatively high-revenue, high-acuity services that can leverage the company’s tertiary-care infrastructure and clinical brand. Fortis also positions oncology as a differentiator in its catchment areas by highlighting international tumor board participation and clinical research affiliations at select centers, competing with peers such as Apollo and Max in the premium private segment; this positioning is referenced in broader corporate and investor materials describing oncology among the focus specialties that support revenue mix and case complexity, as outlined in Fortis Healthcare’s latest investor relations presentations.

In the context of the wider group, the oncology service line is a key contributor to Fortis Healthcare’s case mix and an important use case for its high-end diagnostic and operating theater assets. The program also supports brand visibility via disease awareness campaigns and specialist clinics that can be marketed directly to urban, insured and self-pay patients. Shares of Fortis Healthcare (ISIN INE061F01013) are listed on the National Stock Exchange of India and the BSE in Mumbai; the stock most recently traded around INR 980 on June 15, 2026 on the NSE according to live price data from Kotak Securities.

Fortis cancer care program in brief

• Product: Fortis cancer care program (oncology service line)
• Manufacturer: Fortis Healthcare Ltd.
• Category: New Release/Launch - software & services (hospital oncology program)
• Launch date: Gradual rollout; oncology positioned as a key specialty across Fortis hospitals by the mid-2020s
• MSRP / Price: Not standardized; procedure and package pricing varies by hospital, treatment type and patient profile
• Availability: Offered at major Fortis hospitals across India, including Gurugram, Mohali, Bengaluru and other network facilities
• Target audience: Adult and pediatric patients requiring cancer screening, diagnosis, treatment and follow-up care in private tertiary hospitals
• Key differentiator / USP: Multidisciplinary, hub-and-spoke oncology program combining surgery, systemic therapy, radiation and survivorship services under one coordinated Fortis-branded umbrella

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.